Scolaris Content Display Scolaris Content Display

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
Figuras y tablas -
Figure 1

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Figuras y tablas -
Figure 2

Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Forest plot of comparison: 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, outcome: 1.1 Response ‐ as defined by original studies.
Figuras y tablas -
Figure 3

Forest plot of comparison: 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, outcome: 1.1 Response ‐ as defined by original studies.

Forest plot of comparison: 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, outcome: 1.2 Remission ‐ as defined by original studies.
Figuras y tablas -
Figure 4

Forest plot of comparison: 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, outcome: 1.2 Remission ‐ as defined by original studies.

Forest plot of comparison: 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, outcome: 7.1 Response ‐ as defined by original study.
Figuras y tablas -
Figure 5

Forest plot of comparison: 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, outcome: 7.1 Response ‐ as defined by original study.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 1 Response ‐ as defined by original studies.
Figuras y tablas -
Analysis 1.1

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 1 Response ‐ as defined by original studies.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 2 Remission ‐ as defined by original studies.
Figuras y tablas -
Analysis 1.2

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 2 Remission ‐ as defined by original studies.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 3 Relapse ‐ as defined by original study.
Figuras y tablas -
Analysis 1.3

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 3 Relapse ‐ as defined by original study.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 4 Global state: clinically important change.
Figuras y tablas -
Analysis 1.4

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 4 Global state: clinically important change.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 5 Specific anxiety scale.
Figuras y tablas -
Analysis 1.5

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 5 Specific anxiety scale.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 6 Depressive Symptoms : MADRS change.
Figuras y tablas -
Analysis 1.6

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 6 Depressive Symptoms : MADRS change.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 7 Leaving the study early.
Figuras y tablas -
Analysis 1.7

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 7 Leaving the study early.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 8 At least one adverse effect.
Figuras y tablas -
Analysis 1.8

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 8 At least one adverse effect.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 9 Extrapyramidal side effects ‐ general.
Figuras y tablas -
Analysis 1.9

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 9 Extrapyramidal side effects ‐ general.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 10 Weight ‐ number of patients with significant weight change.
Figuras y tablas -
Analysis 1.10

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 10 Weight ‐ number of patients with significant weight change.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 11 Weight ‐ mean change of weight in kg.
Figuras y tablas -
Analysis 1.11

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 11 Weight ‐ mean change of weight in kg.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 12 Prolactin ‐ increase in ng/mL.
Figuras y tablas -
Analysis 1.12

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 12 Prolactin ‐ increase in ng/mL.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 13 Sedation.
Figuras y tablas -
Analysis 1.13

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 13 Sedation.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 14 Subgroup analysis: older versus younger participants ‐ response ‐ as defined by the original studies.
Figuras y tablas -
Analysis 1.14

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 14 Subgroup analysis: older versus younger participants ‐ response ‐ as defined by the original studies.

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 15 Sensitivity analysis ‐ exclusion of studies with imputed standard deviations.
Figuras y tablas -
Analysis 1.15

Comparison 1 Quetiapine monotherapy versus placebo for generalised anxiety disorder, Outcome 15 Sensitivity analysis ‐ exclusion of studies with imputed standard deviations.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 1 Response ‐ as defined by original studies.
Figuras y tablas -
Analysis 2.1

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 1 Response ‐ as defined by original studies.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 2 Remission ‐ as defined by original studies.
Figuras y tablas -
Analysis 2.2

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 2 Remission ‐ as defined by original studies.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 3 Global state: clinically important change.
Figuras y tablas -
Analysis 2.3

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 3 Global state: clinically important change.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 4 Specific anxiety scale.
Figuras y tablas -
Analysis 2.4

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 4 Specific anxiety scale.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 5 Depressive symptoms.
Figuras y tablas -
Analysis 2.5

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 5 Depressive symptoms.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 6 Leaving the study early.
Figuras y tablas -
Analysis 2.6

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 6 Leaving the study early.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 7 Extrapyramidal side effects ‐ general.
Figuras y tablas -
Analysis 2.7

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 7 Extrapyramidal side effects ‐ general.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 8 Weight ‐ number of of patients with significant weight gain.
Figuras y tablas -
Analysis 2.8

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 8 Weight ‐ number of of patients with significant weight gain.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 9 Weight ‐ mean change of weight in kg.
Figuras y tablas -
Analysis 2.9

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 9 Weight ‐ mean change of weight in kg.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 10 Prolactin ‐ increase in ng/mL.
Figuras y tablas -
Analysis 2.10

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 10 Prolactin ‐ increase in ng/mL.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 11 Sedation.
Figuras y tablas -
Analysis 2.11

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 11 Sedation.

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 12 Sensitivity analysis ‐ exclusion of studies with imputed statistics.
Figuras y tablas -
Analysis 2.12

Comparison 2 Quetiapine monotherapy versus antidepressants for generalised anxiety disorder, Outcome 12 Sensitivity analysis ‐ exclusion of studies with imputed statistics.

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 1 Response ‐ as defined by original study.
Figuras y tablas -
Analysis 3.1

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 1 Response ‐ as defined by original study.

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 2 Remission ‐ as defined by original study.
Figuras y tablas -
Analysis 3.2

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 2 Remission ‐ as defined by original study.

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 3 Global state: clinically important change.
Figuras y tablas -
Analysis 3.3

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 3 Global state: clinically important change.

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 4 Specific anxiety scale.
Figuras y tablas -
Analysis 3.4

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 4 Specific anxiety scale.

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 5 Depressive symptoms: MADRS endpoint.
Figuras y tablas -
Analysis 3.5

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 5 Depressive symptoms: MADRS endpoint.

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 6 Leaving the study early.
Figuras y tablas -
Analysis 3.6

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 6 Leaving the study early.

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 7 Weight ‐ mean change of weight in kg.
Figuras y tablas -
Analysis 3.7

Comparison 3 Quetiapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 7 Weight ‐ mean change of weight in kg.

Comparison 4 Quetiapine monotherapy versus placebo for social phobia, Outcome 1 Response ‐ as defined by original study.
Figuras y tablas -
Analysis 4.1

Comparison 4 Quetiapine monotherapy versus placebo for social phobia, Outcome 1 Response ‐ as defined by original study.

Comparison 4 Quetiapine monotherapy versus placebo for social phobia, Outcome 2 Global state: clinically important change.
Figuras y tablas -
Analysis 4.2

Comparison 4 Quetiapine monotherapy versus placebo for social phobia, Outcome 2 Global state: clinically important change.

Comparison 4 Quetiapine monotherapy versus placebo for social phobia, Outcome 3 Specific anxiety scale.
Figuras y tablas -
Analysis 4.3

Comparison 4 Quetiapine monotherapy versus placebo for social phobia, Outcome 3 Specific anxiety scale.

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 1 Response ‐ as defined by original study.
Figuras y tablas -
Analysis 5.1

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 1 Response ‐ as defined by original study.

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 2 Global state: clinically important change.
Figuras y tablas -
Analysis 5.2

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 2 Global state: clinically important change.

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 3 Specific anxiety scale: BSPS‐endpoint.
Figuras y tablas -
Analysis 5.3

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 3 Specific anxiety scale: BSPS‐endpoint.

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 4 Leaving the study early.
Figuras y tablas -
Analysis 5.4

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 4 Leaving the study early.

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 5 Weight ‐ number of patients with significant weight gain.
Figuras y tablas -
Analysis 5.5

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 5 Weight ‐ number of patients with significant weight gain.

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 6 Weight ‐ mean change of weight in kg.
Figuras y tablas -
Analysis 5.6

Comparison 5 Olanzapine monotherapy versus placebo for social phobia, Outcome 6 Weight ‐ mean change of weight in kg.

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 1 Response ‐ as defined by original study.
Figuras y tablas -
Analysis 6.1

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 1 Response ‐ as defined by original study.

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 2 Remission ‐ as defined by original study.
Figuras y tablas -
Analysis 6.2

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 2 Remission ‐ as defined by original study.

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 3 Specific anxiety scale.
Figuras y tablas -
Analysis 6.3

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 3 Specific anxiety scale.

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 4 Depressive symptoms.
Figuras y tablas -
Analysis 6.4

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 4 Depressive symptoms.

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 5 At least one adverse effect.
Figuras y tablas -
Analysis 6.5

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 5 At least one adverse effect.

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 6 Leaving the study early.
Figuras y tablas -
Analysis 6.6

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 6 Leaving the study early.

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 7 Weight ‐ number of patients with significant weight gain.
Figuras y tablas -
Analysis 6.7

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 7 Weight ‐ number of patients with significant weight gain.

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 8 Weight ‐ mean change of weight in kg.
Figuras y tablas -
Analysis 6.8

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 8 Weight ‐ mean change of weight in kg.

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 9 Sedation.
Figuras y tablas -
Analysis 6.9

Comparison 6 Olanzapine versus placebo added to antidepressants for generalised anxiety disorder, Outcome 9 Sedation.

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 1 Response ‐ as defined by original study.
Figuras y tablas -
Analysis 7.1

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 1 Response ‐ as defined by original study.

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 2 Remission.
Figuras y tablas -
Analysis 7.2

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 2 Remission.

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 3 Global state: clinically important change.
Figuras y tablas -
Analysis 7.3

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 3 Global state: clinically important change.

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 4 Specific anxiety scale.
Figuras y tablas -
Analysis 7.4

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 4 Specific anxiety scale.

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 5 Depressive symptoms: MADRS endpoint.
Figuras y tablas -
Analysis 7.5

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 5 Depressive symptoms: MADRS endpoint.

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 6 Leaving the study early.
Figuras y tablas -
Analysis 7.6

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 6 Leaving the study early.

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 7 Additional benzodiazepine treatment ‐ number of patients.
Figuras y tablas -
Analysis 7.7

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 7 Additional benzodiazepine treatment ‐ number of patients.

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 8 Weight ‐ mean change of weight in kg.
Figuras y tablas -
Analysis 7.8

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 8 Weight ‐ mean change of weight in kg.

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 9 Sedation.
Figuras y tablas -
Analysis 7.9

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 9 Sedation.

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 10 Extrapyramidal side effects ‐ use of antiparkinson medication.
Figuras y tablas -
Analysis 7.10

Comparison 7 Risperidone versus placebo added to antidepressants for generalised anxiety disorder, Outcome 10 Extrapyramidal side effects ‐ use of antiparkinson medication.

Comparison 1. Quetiapine monotherapy versus placebo for generalised anxiety disorder

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Response ‐ as defined by original studies Show forest plot

4

2262

Odds Ratio (M‐H, Random, 95% CI)

2.21 [1.10, 4.45]

2 Remission ‐ as defined by original studies Show forest plot

4

2262

Odds Ratio (M‐H, Random, 95% CI)

1.83 [1.07, 3.12]

3 Relapse ‐ as defined by original study Show forest plot

1

433

Odds Ratio (M‐H, Random, 95% CI)

0.18 [0.10, 0.30]

4 Global state: clinically important change Show forest plot

4

2262

Odds Ratio (M‐H, Random, 95% CI)

2.28 [1.01, 5.14]

5 Specific anxiety scale Show forest plot

5

Mean Difference (IV, Random, 95% CI)

Subtotals only

5.1 Short‐term HAM‐A change

4

2196

Mean Difference (IV, Random, 95% CI)

‐2.58 [‐4.00, ‐1.16]

5.2 Long‐term HAM‐A‐change

1

432

Mean Difference (IV, Random, 95% CI)

‐2.04 [‐3.25, ‐0.83]

6 Depressive Symptoms : MADRS change Show forest plot

3

Mean Difference (IV, Random, 95% CI)

Subtotals only

6.1 Short‐term MADRS‐change

2

867

Mean Difference (IV, Random, 95% CI)

‐3.05 [‐5.99, ‐0.10]

6.2 Long‐term MADRS change

1

432

Mean Difference (IV, Random, 95% CI)

‐1.85 [‐2.94, ‐0.76]

7 Leaving the study early Show forest plot

5

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

7.1 Short‐term adverse events

4

2262

Odds Ratio (M‐H, Random, 95% CI)

3.76 [2.64, 5.34]

7.2 Long‐term adverse events

1

433

Odds Ratio (M‐H, Random, 95% CI)

0.62 [0.20, 1.92]

8 At least one adverse effect Show forest plot

1

450

Odds Ratio (M‐H, Random, 95% CI)

1.84 [1.26, 2.69]

9 Extrapyramidal side effects ‐ general Show forest plot

5

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

9.1 Short‐term

4

2262

Odds Ratio (M‐H, Random, 95% CI)

1.80 [1.12, 2.90]

9.2 Long‐term

1

433

Odds Ratio (M‐H, Random, 95% CI)

2.39 [0.61, 9.36]

10 Weight ‐ number of patients with significant weight change Show forest plot

5

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

10.1 Short‐term

4

2262

Odds Ratio (M‐H, Random, 95% CI)

2.39 [1.23, 4.65]

10.2 Long‐term

1

433

Odds Ratio (M‐H, Random, 95% CI)

1.00 [0.20, 5.03]

11 Weight ‐ mean change of weight in kg Show forest plot

4

2201

Mean Difference (IV, Random, 95% CI)

0.63 [0.40, 0.86]

12 Prolactin ‐ increase in ng/mL Show forest plot

1

437

Mean Difference (IV, Random, 95% CI)

0.7 [‐1.09, 2.49]

13 Sedation Show forest plot

5

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

13.1 Short‐term

4

2262

Odds Ratio (M‐H, Random, 95% CI)

4.48 [2.65, 7.59]

13.2 Long‐term

1

433

Odds Ratio (M‐H, Random, 95% CI)

11.31 [0.62, 205.84]

14 Subgroup analysis: older versus younger participants ‐ response ‐ as defined by the original studies Show forest plot

4

2262

Odds Ratio (IV, Random, 95% CI)

2.21 [1.10, 4.45]

14.1 Younger participants (< 65 years)

3

1812

Odds Ratio (IV, Random, 95% CI)

1.49 [1.22, 1.81]

14.2 Older participants (> 65 years)

1

450

Odds Ratio (IV, Random, 95% CI)

6.86 [4.53, 10.39]

15 Sensitivity analysis ‐ exclusion of studies with imputed standard deviations Show forest plot

3

Mean Difference (IV, Random, 95% CI)

Subtotals only

15.1 HAM‐A change

3

1777

Mean Difference (IV, Random, 95% CI)

‐1.00 [‐5.26, ‐0.74]

15.2 MADRS change

1

448

Mean Difference (IV, Random, 95% CI)

‐4.72 [‐7.52, ‐1.92]

15.3 Weight ‐ mean change of weight in kg

1

436

Mean Difference (IV, Random, 95% CI)

0.70 [0.23, 1.17]

Figuras y tablas -
Comparison 1. Quetiapine monotherapy versus placebo for generalised anxiety disorder
Comparison 2. Quetiapine monotherapy versus antidepressants for generalised anxiety disorder

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Response ‐ as defined by original studies Show forest plot

2

858

Odds Ratio (M‐H, Random, 95% CI)

1.11 [0.84, 1.46]

2 Remission ‐ as defined by original studies Show forest plot

2

858

Odds Ratio (M‐H, Random, 95% CI)

1.01 [0.76, 1.34]

3 Global state: clinically important change Show forest plot

2

858

Odds Ratio (M‐H, Random, 95% CI)

1.14 [0.86, 1.51]

4 Specific anxiety scale Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Subtotals only

4.1 HAM‐A change

2

842

Mean Difference (IV, Random, 95% CI)

‐0.35 [‐1.73, 1.03]

5 Depressive symptoms Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

5.1 MADRS change

1

410

Mean Difference (IV, Random, 95% CI)

‐0.40 [‐2.43, 1.63]

6 Leaving the study early Show forest plot

2

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

6.1 Adverse events

2

858

Odds Ratio (M‐H, Random, 95% CI)

2.18 [1.44, 3.31]

7 Extrapyramidal side effects ‐ general Show forest plot

2

858

Odds Ratio (M‐H, Random, 95% CI)

0.88 [0.51, 1.51]

8 Weight ‐ number of of patients with significant weight gain Show forest plot

2

858

Odds Ratio (M‐H, Random, 95% CI)

2.55 [0.43, 15.00]

9 Weight ‐ mean change of weight in kg Show forest plot

2

845

Mean Difference (IV, Random, 95% CI)

0.96 [0.66, 1.25]

10 Prolactin ‐ increase in ng/mL Show forest plot

1

437

Mean Difference (IV, Random, 95% CI)

‐2.53 [‐5.06, ‐0.00]

11 Sedation Show forest plot

2

858

Odds Ratio (M‐H, Random, 95% CI)

2.80 [1.95, 4.02]

12 Sensitivity analysis ‐ exclusion of studies with imputed statistics Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

12.1 HAM‐A change

1

432

Mean Difference (IV, Random, 95% CI)

0.55 [‐1.62, 2.72]

12.2 Weight ‐ mean change in kg

1

434

Mean Difference (IV, Random, 95% CI)

0.8 [0.44, 1.16]

Figuras y tablas -
Comparison 2. Quetiapine monotherapy versus antidepressants for generalised anxiety disorder
Comparison 3. Quetiapine versus placebo added to antidepressants for generalised anxiety disorder

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Response ‐ as defined by original study Show forest plot

1

22

Odds Ratio (M‐H, Random, 95% CI)

1.44 [0.27, 7.71]

2 Remission ‐ as defined by original study Show forest plot

1

22

Odds Ratio (M‐H, Random, 95% CI)

2.57 [0.36, 18.33]

3 Global state: clinically important change Show forest plot

1

22

Odds Ratio (M‐H, Random, 95% CI)

1.44 [0.27, 7.71]

4 Specific anxiety scale Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

4.1 HAM‐A endpoint

1

22

Mean Difference (IV, Random, 95% CI)

‐1.91 [‐8.74, 4.92]

5 Depressive symptoms: MADRS endpoint Show forest plot

1

22

Mean Difference (IV, Random, 95% CI)

‐1.37 [‐6.92, 4.18]

6 Leaving the study early Show forest plot

1

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

6.1 Any reason

1

22

Odds Ratio (M‐H, Random, 95% CI)

8.33 [0.78, 89.47]

6.2 Adverse events

1

22

Odds Ratio (M‐H, Random, 95% CI)

13.80 [0.65, 295.25]

6.3 Inefficacy

1

22

Odds Ratio (M‐H, Random, 95% CI)

0.30 [0.01, 8.32]

7 Weight ‐ mean change of weight in kg Show forest plot

1

22

Mean Difference (IV, Random, 95% CI)

0.0 [‐1.35, 1.35]

Figuras y tablas -
Comparison 3. Quetiapine versus placebo added to antidepressants for generalised anxiety disorder
Comparison 4. Quetiapine monotherapy versus placebo for social phobia

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Response ‐ as defined by original study Show forest plot

1

15

Odds Ratio (M‐H, Random, 95% CI)

3.24 [0.13, 80.99]

2 Global state: clinically important change Show forest plot

1

15

Odds Ratio (M‐H, Random, 95% CI)

7.62 [0.33, 175.01]

3 Specific anxiety scale Show forest plot

1

15

Mean Difference (IV, Random, 95% CI)

31.10 [‐85.41, 147.61]

3.1 BSPS endpoint

1

15

Mean Difference (IV, Random, 95% CI)

31.10 [‐85.41, 147.61]

Figuras y tablas -
Comparison 4. Quetiapine monotherapy versus placebo for social phobia
Comparison 5. Olanzapine monotherapy versus placebo for social phobia

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Response ‐ as defined by original study Show forest plot

1

12

Odds Ratio (M‐H, Random, 95% CI)

8.56 [0.34, 212.94]

2 Global state: clinically important change Show forest plot

1

12

Odds Ratio (M‐H, Random, 95% CI)

8.56 [0.34, 212.94]

3 Specific anxiety scale: BSPS‐endpoint Show forest plot

1

12

Mean Difference (IV, Random, 95% CI)

‐22.50 [‐35.25, ‐9.75]

4 Leaving the study early Show forest plot

1

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

4.1 Any reason

1

12

Odds Ratio (M‐H, Random, 95% CI)

1.13 [0.11, 11.60]

4.2 Adverse event

1

12

Odds Ratio (M‐H, Random, 95% CI)

0.67 [0.03, 14.03]

5 Weight ‐ number of patients with significant weight gain Show forest plot

1

12

Odds Ratio (M‐H, Random, 95% CI)

0.2 [0.01, 6.04]

6 Weight ‐ mean change of weight in kg Show forest plot

1

12

Mean Difference (IV, Random, 95% CI)

‐0.36 [‐2.35, 1.63]

Figuras y tablas -
Comparison 5. Olanzapine monotherapy versus placebo for social phobia
Comparison 6. Olanzapine versus placebo added to antidepressants for generalised anxiety disorder

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Response ‐ as defined by original study Show forest plot

1

24

Odds Ratio (M‐H, Random, 95% CI)

7.86 [0.75, 82.13]

2 Remission ‐ as defined by original study Show forest plot

1

24

Odds Ratio (M‐H, Random, 95% CI)

5.5 [0.51, 59.01]

3 Specific anxiety scale Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

3.1 HAM‐A endpoint

1

21

Mean Difference (IV, Random, 95% CI)

‐8.30 [‐14.98, ‐1.62]

4 Depressive symptoms Show forest plot

1

Mean Difference (IV, Random, 95% CI)

Subtotals only

4.1 HAM‐D endpoint

1

21

Mean Difference (IV, Random, 95% CI)

‐5.6 [‐10.24, ‐0.96]

5 At least one adverse effect Show forest plot

1

24

Odds Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

6 Leaving the study early Show forest plot

1

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

6.1 Any reason

1

24

Odds Ratio (M‐H, Random, 95% CI)

3.57 [0.53, 23.95]

6.2 Adverse events

1

24

Odds Ratio (M‐H, Random, 95% CI)

5.5 [0.51, 59.01]

7 Weight ‐ number of patients with significant weight gain Show forest plot

1

24

Odds Ratio (M‐H, Random, 95% CI)

5.95 [0.26, 138.25]

8 Weight ‐ mean change of weight in kg Show forest plot

1

24

Mean Difference (IV, Random, 95% CI)

4.7 [3.26, 6.14]

9 Sedation Show forest plot

1

24

Odds Ratio (M‐H, Random, 95% CI)

15.40 [1.47, 160.97]

Figuras y tablas -
Comparison 6. Olanzapine versus placebo added to antidepressants for generalised anxiety disorder
Comparison 7. Risperidone versus placebo added to antidepressants for generalised anxiety disorder

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Response ‐ as defined by original study Show forest plot

2

457

Odds Ratio (M‐H, Random, 95% CI)

1.19 [0.62, 2.31]

2 Remission Show forest plot

1

417

Odds Ratio (M‐H, Random, 95% CI)

1.07 [0.65, 1.78]

3 Global state: clinically important change Show forest plot

1

40

Odds Ratio (M‐H, Random, 95% CI)

2.27 [0.64, 8.11]

4 Specific anxiety scale Show forest plot

2

Mean Difference (IV, Random, 95% CI)

Subtotals only

4.1 HAM‐A change

2

408

Mean Difference (IV, Random, 95% CI)

‐1.56 [‐4.90, 1.77]

5 Depressive symptoms: MADRS endpoint Show forest plot

1

39

Mean Difference (IV, Random, 95% CI)

‐0.10 [‐2.33, 2.13]

6 Leaving the study early Show forest plot

2

Odds Ratio (M‐H, Random, 95% CI)

Subtotals only

6.1 Any reason

2

457

Odds Ratio (M‐H, Random, 95% CI)

1.19 [0.78, 1.79]

6.2 Adverse event

2

457

Odds Ratio (M‐H, Random, 95% CI)

2.26 [1.08, 4.74]

6.3 Inefficacy

1

417

Odds Ratio (M‐H, Random, 95% CI)

1.56 [0.59, 4.12]

7 Additional benzodiazepine treatment ‐ number of patients Show forest plot

1

40

Odds Ratio (M‐H, Random, 95% CI)

1.0 [0.29, 3.48]

8 Weight ‐ mean change of weight in kg Show forest plot

2

445

Mean Difference (IV, Random, 95% CI)

0.34 [‐0.72, 1.40]

9 Sedation Show forest plot

1

40

Odds Ratio (M‐H, Random, 95% CI)

4.64 [1.02, 21.00]

10 Extrapyramidal side effects ‐ use of antiparkinson medication Show forest plot

1

40

Odds Ratio (M‐H, Random, 95% CI)

0.0 [0.0, 0.0]

Figuras y tablas -
Comparison 7. Risperidone versus placebo added to antidepressants for generalised anxiety disorder